ViTToria Biotherapeutics, co-founded by Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology, has dosed the first patient in its Phase 1 clinical trial for VIPER-101. VIPER-101 is an autologous cell therapy designed to treat relapsed and/or refractory (r/r) T cell lymphoma, a severe disease with currently limited treatment options. VIPER-101 incorporates Vittoria’s proprietary Senza5™ platform which integrates CD5 gene-editing technology with a rapid, 5-day manufacturing process. This innovative approach is intended to enhance the efficacy and safety profile of conventional autologous cell therapies, offering new hope to patients whose cancers have not responded to traditional lines of treatment. Read more here.